Tuo Wei

Dr. Tuo Wei

Institute of Zoology, Chinese Academy of Sciences, Beijing, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
QCQIANG CHENG
QIANG CHENG
Tuo WeiTuo Wei
Tuo Wei
LFLukas Farbiak
Lukas Farbiak
LJLindsay T. Johnson
Lindsay T. Johnson
SDSean A. Dilliard
Sean A. Dilliard
DSDaniel Siegwart
Daniel Siegwart

27 April 2012 in ACS Nano
Verified
Journal Article
Closed access
KHKeyang Huang
Keyang Huang
HMHuili Ma
Huili Ma
JLJuan Liu
Juan Liu
SHShuaidong Huo
Shuaidong Huo
AKAnil Kumar
Anil Kumar
XLXingjie Liang
Xingjie Liang

4 February 2021 in Nature Materials
Verified
Journal Article
Closed access
PDF file
SLShuai Liu
Shuai Liu
QCQIANG CHENG
QIANG CHENG
Tuo WeiTuo Wei
Tuo Wei
XYXueliang Yu
Xueliang Yu
LJLindsay T. Johnson
Lindsay T. Johnson
DSDaniel Siegwart
Daniel Siegwart

26 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
Tuo WeiTuo Wei
Tuo Wei
QCQIANG CHENG
QIANG CHENG
YMYi-Li Min
Yi-Li Min
EOEric N. Olson
Eric N. Olson
DSDaniel Siegwart
Daniel Siegwart
CRISPR-Cas9 has emerged as a powerful technology that relies on Cas9/sgRNA ribonucleoprotein complexes (RNPs) to target and edit DNA. However, many therapeutic targets cannot currently be accessed due to the lack of carriers that can deliver RNPs systemically. Here, we report a generalizable methodology that allows engineering of modified lipid nanoparticles to efficiently deliver RNPs into cells and edit tissues including muscle, brain, liver, and lungs. Intravenous injection facilitated tissue-specific, multiplexed editing of six genes in mouse lungs. High carrier potency was leveraged to create organ-specific cancer models in livers and lungs of mice though facile knockout of multiple genes. The developed carriers were also able to deliver RNPs to restore dystrophin expression in DMD mice and significantly decrease serum PCSK9 level in C57BL/6 mice. Application of this generalizable strategy will facilitate broad nanoparticle development for a variety of disease targets amenable to protein delivery and precise gene correction approaches.

31 October 2022 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
XWXu Wang
Xu Wang
SLShuai Liu
Shuai Liu
YSYehui Sun
Yehui Sun
XYXueliang Yu
Xueliang Yu
SLSang M. Lee
Sang M. Lee
DSDaniel Siegwart
Daniel Siegwart

1 November 2023 in Advanced Materials
Verified
Journal Article
Closed access
YZYan Zong
Yan Zong
YLYi Lin
Yi Lin
Tuo WeiTuo Wei
Tuo Wei
QCQIANG CHENG
QIANG CHENG